Prognostic and Immunological Roles of CES2 in Breast Cancer and Potential Application of CES2-Targeted Fluorescent Probe DDAB in Breast Surgery

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi:10.1038/s41572-019-0111-2
   PubMed Web of Science ®Google Scholar
• Hamann M, Grill S, Struck J, et al. Detection of early breast cancer beyond mammographic screening: a promising biomarker panel. Biomark Med. 2019;13(13):1107–1117. doi:10.2217/bmm-2019-0085
   PubMed Web of Science ®Google Scholar
• Mayor S. Screening for early breast cancer reduces invasive cancer, study finds. BMJ. 2015;351:h6576. doi:10.1136/bmj.h6576
   PubMedGoogle Scholar
• Wang D, Zou L, Jin Q, Hou J, Ge G, Yang L. Human carboxylesterases: a comprehensive review. Acta Pharm Sin B. 2018;8(5):699–712. doi:10.1016/j.apsb.2018.05.005
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013;344(3):665–672. doi:10.1124/jpet.112.201640
   PubMed Web of Science ®Google Scholar
• Imai T, Ohura K. The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab. 2010;11(9):793–805. doi:10.2174/138920010794328904
   PubMed Web of Science ®Google Scholar
• Nishi K, Huang H, Kamita SG, Kim IH, Morisseau C, Hammock BD. Characterization of pyrethroid hydrolysis by the human liver carboxylesterases hCE-1 and hCE-2. Arch Biochem Biophys. 2006;445(1):115–123. doi:10.1016/j.abb.2005.11.005
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2009;37(2):264–267. doi:10.1124/dmd.108.024943
   PubMed Web of Science ®Google Scholar
• Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23–44. doi:10.1016/j.clinthera.2005.01.005
   PubMed Web of Science ®Google Scholar
• Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013;19(5):1159–1168. doi:10.1158/1078-0432.ccr-12-1184
   PubMed Web of Science ®Google Scholar
• Hatfield MJ, Tsurkan L, Garrett M, et al. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol. 2011;81(1):24–31. doi:10.1016/j.bcp.2010.09.001
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun L, Sun Y, et al. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway. Exp Cell Res. 2020;389(1):111856. doi:10.1016/j.yexcr.2020.111856
   PubMed Web of Science ®Google Scholar
• Uchida K, Otake K, Tanaka K, et al. Clinical implications of CES2 RNA expression in neuroblastoma. J Pediatr Surg. 2013;48(3):502–509. doi:10.1016/j.jpedsurg.2012.10.004
   PubMed Web of Science ®Google Scholar
• Chen Y, Capello M, Rios Perez MV, et al. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Mol Metab. 2022;56:101426. doi:10.1016/j.molmet.2021.101426
   PubMed Web of Science ®Google Scholar
• Jin Q, Feng L, Wang DD, et al. A highly selective near-infrared fluorescent probe for carboxylesterase 2 and its bioimaging applications in living cells and animals. Biosens Bioelectron. 2016;83:193–199. doi:10.1016/j.bios.2016.04.075
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68(6):394–424. doi:10.3322/caac.21492
   Web of Science ®Google Scholar
• Satoh T, Hosokawa M. Structure, function and regulation of carboxylesterases. Chem Biol Interact. 2006;162(3):195–211. doi:10.1016/j.cbi.2006.07.001
   PubMed Web of Science ®Google Scholar
• Zhang C, Xu Y, Zhong Q, et al. In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2. PLoS One. 2014;9(4):e93819. doi:10.1371/journal.pone.0093819
   PubMed Web of Science ®Google Scholar
• Liu D, Gao J, Zhang C, Ren X, Liu Y, Xu Y. Identification of carboxylesterases expressed in rat intestine and effects of their hydrolyzing activity in predicting first-pass metabolism of ester prodrugs. Die Pharmazie. 2011;66(11):888–893.
   PubMed Web of Science ®Google Scholar
• Crow JA, Borazjani A, Potter PM, Ross MK. Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Pharmacol. 2007;221(1):1–12. doi:10.1016/j.taap.2007.03.002
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang C, He W, Liu D. Regulations of xenobiotics and endobiotics on carboxylesterases: a comprehensive review. Eur J Drug Metab Pharmacokinet. 2016;41(4):321–330. doi:10.1007/s13318-016-0326-5
   PubMed Web of Science ®Google Scholar
• Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017;24(1):3–15. doi:10.1007/s12282-016-0698-z
   PubMed Web of Science ®Google Scholar
• Lee KH, Kim EY, Yun JS, et al. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. BMC Cancer. 2018;18(1):938. doi:10.1186/s12885-018-4832-5
   PubMedGoogle Scholar
• Xu Q, Chen S, Hu Y, Huang W. Landscape of immune microenvironment under immune cell infiltration pattern in breast cancer. Front Immunol. 2021;12:711433. doi:10.3389/fimmu.2021.711433
   PubMed Web of Science ®Google Scholar
• Dintzis SM, Hansen S, Harrington KM, et al. Real-time visualization of breast carcinoma in pathology specimens from patients receiving fluorescent tumor-marking agent tozuleristide. Arch Pathol Lab Med. 2019;143(9):1076–1083. doi:10.5858/arpa.2018-0197-OA
   PubMed Web of Science ®Google Scholar
• Lu G, van den Berg NS, Martin BA, et al. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a Phase 1 single-centre, open-label, single-arm, dose-escalation study. Lancet Gastroenterol Hepatol. 2020;5(8):753–764. doi:10.1016/s2468-1253(20)30088-1
   PubMed Web of Science ®Google Scholar